Intestinal necrosis in a patient with rheumatoid arthritis receiving anti-TNF treatment

Acta Chirurgica Belgica

Volumn 106, Issue 2, 2006, Pages 225-227

  Ruppert, M ^a,b   De Clerck, L ^a   Van Offel, J ^a   Hubens, G ^a   Balliu, L ^a   Vaneerdeweg, W ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anti TNF treatment; Intestinal necrosis; Rheumatoid Arthritis; Vasculitis

Indexed keywords

EID: 33646517296     PISSN: 00015458     EISSN: 25770160     Source Type: Journal    
DOI: 10.1080/00015458.2006.11679877     Document Type: Article

References (10)

1. BERTHELOT J. M., GLEMAREC J. Lethal medium-vessel panarteritis mimicking deep sepsis following etanercept and minocycline therapy in a patient with severe rheumatoid arthritis. Rheumatology (Oxford), 2002, 41: 703-5.
2. CUNNANE G., WARNOCK M. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum, 2002, 47: 445-9.
3. MATSUMOTO Y. The rheumatoid vasculitis and malignant rheumatoid arthritis. Nippon Kinsho, 2002, 60: 2408-16
4. LIPSKY P. E., VAN DER HEIJDE D. M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med, 2000, 343: 1594-602.
5. DEN BROEDER A. A., VAN DEN HOOGEN F. H. Isolated digital vasculitis in a patient rheumatoid arthritis: good response to tumour necrosis factor alpha blocking treatment. Ann Rheum Dis, 2001, 60: 538-9.
6. BARTOLUCCI P., RAMANOELINA J. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford), 2002, 41: 1126-32.
7. ANTONI C., BRAUN J. Side-effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol, 2002, 20: S152-7.
8. SHAKOOR N., MICHALSKA M. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet, 2002, 359: 579-80.
9. GALARI N. A., WERTH V. P. Leukoclastic vasculitis due to etanercept. J Rheumatol, 2000, 27: 2041-4.
10. ST. CLAIR E. W., WAGNER C. L. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomize, double-blind, placebo-controlled trial. Arthritis Rheum, 2002, 46: 1451-9.